Alnylam Pharmaceuticals Aktie
382,20
EUR
-1,60
EUR
-0,42
%
445,10
USD
-1,12
USD
-0,25
%
Werbung
Alnylam Pharmaceuticals Aktie Analyse
30.03.17 | Alnylam Pharmaceuticals Neutral | UBS AG | |
24.11.09 | Alnylam Pharmaceuticals hold | ROTH Capital Partners, LLC | |
26.02.09 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
25.02.09 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
15.09.08 | Alnylam Pharmaceuticals market weight | Thomas Weisel Partners LLC | |
21.08.08 | Alnylam Pharmaceuticals | Focus Money | |
10.10.07 | Alnylam Pharmaceuticals market perform | Piper Jaffray & Co. | |
14.08.07 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
Werbung
|
Werbung
Werbung